Literature DB >> 17714697

Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q).

J Stenzel1, F Worek, P Eyer.   

Abstract

The potential of the most active pyridinium-4-aldoximes, such as obidoxime and trimedoxime, to reactivate phosphorylated acetylcholinesterase is not fully exploited because of inevitable formation of phosphoryloximes (POXs) with extremely high anticholinesterase activity. Hence, a topochemical equilibrium is expected at the active site, with the freshly reactivated enzyme being rapidly re-inhibited by POX produced during reactivation. In the present study, dimethylphosphoryl-, diethylphosphoryl-, and diisopropyl-obidoxime conjugates were generated and isolated in substance. Their inhibition rate of acetylcholinesterase from human red cell membranes was by a factor of 2250, 480 and 600 higher than that observed with paraoxon-methyl, paraoxon-ethyl, and diisopropyl phosphorofluoridate, respectively. All three POXs were hydrolyzed by human paraoxonase (PON1), with the alloenzyme PON1192Q being about 50-fold more active than PON1192R. The rate of hydrolysis, yielding obidoxime, was 1:6:0.03 for the three POXs, respectively. The rate of non-enzymic degradation, yielding obidoxime mononitrile, was similar with the three POXs and showed a high dependency on the reaction temperature (activation energy 83 kJ/mol), while enzymic hydrolysis required less energy (16 kJ/mol). To determine POX-hydrolase activity, we preferred a reaction temperature of 20 degrees C to reduce the noise of spontaneous degradation. A plot of POX-hydrolase versus salt-stimulated paraoxonase activity showed a highly discriminating power towards the PON1Q192R alloenzymes, which may be based on repulsive forces of the quaternary nitrogen atoms of the protonated arginine subtype and the bisquaternary POXs. It is concluded that the pharmacogenetic PON1Q192R polymorphism may be another contributor to the large variability of susceptible subjects seen in obidoxime-treated patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17714697     DOI: 10.1016/j.bcp.2007.07.013

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes.

Authors:  Karen Huen; Kim Harley; Asa Bradman; Brenda Eskenazi; Nina Holland
Journal:  Toxicol Appl Pharmacol       Date:  2010-01-04       Impact factor: 4.219

2.  In vitro ability of currently available oximes to reactivate organophosphate pesticide-inhibited human acetylcholinesterase and butyrylcholinesterase.

Authors:  Daniel Jun; Lucie Musilova; Kamil Musilek; Kamil Kuca
Journal:  Int J Mol Sci       Date:  2011-03-23       Impact factor: 5.923

3.  Kinetic Processes in Enzymatic Nanoreactors for In Vivo Detoxification.

Authors:  Zukhra Shajhutdinova; Tatiana Pashirova; Patrick Masson
Journal:  Biomedicines       Date:  2022-03-27

4.  Developmental changes in PON1 enzyme activity in young children and effects of PON1 polymorphisms.

Authors:  Karen Huen; Kim Harley; Jordan Brooks; Alan Hubbard; Asa Bradman; Brenda Eskenazi; Nina Holland
Journal:  Environ Health Perspect       Date:  2009-06-09       Impact factor: 9.031

5.  Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF).

Authors:  Florian Eyer; Darren M Roberts; Nicholas A Buckley; Michael Eddleston; Horst Thiermann; Franz Worek; Peter Eyer
Journal:  Biochem Pharmacol       Date:  2009-05-09       Impact factor: 5.858

6.  Validation of PON1 enzyme activity assays for longitudinal studies.

Authors:  Karen Huen; Rebecca Richter; Clement Furlong; Brenda Eskenazi; Nina Holland
Journal:  Clin Chim Acta       Date:  2008-12-24       Impact factor: 3.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.